Q Fever is a zoonotic disease caused by the intracellular bacteria Coxiella burnetii, a species of alpha-Proteobacteria related to Legionella pneumophila. It is robust and one of the most infectious organisms and is usually acquired by the inhalation of particles from infected animals.
The disease is distributed globally and is a scheduled WorkCover compensable disease in Australia.
The incubation period is 14-39 days.
Most commonly, a mild influenza-like illness occurs, but more severe symptoms and serious complications – pneumonia, hepatitis, endocarditis, Post Q-Fever Debility Syndrome (PQDS) – sometimes occur. Hepatomegaly occurs in 50% of cases.
Many people infected with Q Fever may show little or no signs of illness.
The duration of the initial illness is 2 days to 2 weeks after which it usually resolves without permanent effects. However, complications such as endocarditis, osteomyelitis, arteritis and granulomatous disease of liver and testes, may develop after 3-20 years and may be fatal.
Coxiella burnetti can be resistant to heat and desiccation, and is highly infectious by the aerosol route. A single inhaled organism may produce clinical illness. Indeed, in [non-human] primates, the dose to kill 50 per cent of the primates was found to be 1.7 organisms. It therefore has some potential in biological warfare.
Q-Fever is a vaccine-preventable disease. It is a notifiable disease in Victoria.
Every year, some 575 cases are notified in Australia – mainly from Queensland and New South Wales. Some doctors in Queensland have deemed it necessary to administer the vaccine to rural youth, even though it has not been approved for children, because of the high-risk of Q fever in the area.
In 2000, the Australian Government (and then the states), introduced a vaccination program for abattoir workers, cattle and sheep farmers and others working in the meat industry.
The disease was reported to be endemic to California during the 1950s. In certain regions of Europe (The Netherlands, France and Spain) the organism is highly prevalent, being the second most common etiology of community-acquired pneumonia and causing 5-8% of endocarditis cases.
Multiple reports of clusters have been described for many years, especially from Europe, Israel and the USA.
Australia is the only nation which utilises a vaccine for the prevention of Q-Fever.
The vaccine used to protect against Q-Fever is Q-Vax, a purified suspension of formalin-inactivated C.burnetii. Special care with the vaccine is required as severe reactions may occur. Revaccination is contraindicated.
Testing requires two visits to a health provider about one week apart. People who test positive are immune and don’t receive the vaccine. People who test negative can be safely vaccinated.
Vaccines cannot be given without prior skin testing and antibody checking – done on the same day.
Immunity to Q Fever typically develops about 15 days after vaccination. If you have been vaccinated and you work in a high risk environment, you should not commence work until after this time.
If you test positive and do not need the vaccine you are protected and can start work once your results are confirmed – usually once your record is entered onto the Q Fever Register.
Large scale vaccination of cattle in Slovakia and Bulgaria appears to have been effective. This has been accomplished with an inactivated phase 1 vaccine.
In Israel, an inactivated bivalent vaccine (combined with chlamydia) has been used in small ruminants.
Doxycycline is the treatment of choice for acute Q fever.
Antibiotic treatment is most effective when initiated within the first 3 days of illness.
The Australian Q Fever Register was established in 2002 and provides information on the immune status of individuals by password access.